202197-78-2 Usage
Description
4-CHLORO-7-IODOQUINAZOLINE is a heterocyclic chemical compound with the molecular formula C8H5ClIN2. It features a quinazoline ring system, which is adorned with chlorine and iodine substituents. 4-CHLORO-7-IODOQUINAZOLINE holds promise in the pharmaceutical and agrochemical sectors, primarily due to its potential as a building block in the synthesis of a variety of organic compounds. Additionally, it may exhibit biological activity, positioning it as a prospective drug candidate or a precursor to other biologically active molecules. Further research is essential to fully explore and comprehend the compound's potential applications and properties.
Uses
Used in Pharmaceutical Industry:
4-CHLORO-7-IODOQUINAZOLINE is used as a building block for the synthesis of various organic compounds, which can be utilized in the development of new pharmaceuticals. Its unique structure and the presence of halogen substituents may contribute to its potential as a drug candidate, offering novel therapeutic options.
Used in Agrochemical Industry:
In the agrochemical field, 4-CHLORO-7-IODOQUINAZOLINE is employed as a precursor to other biologically active molecules. Its chemical properties and structural features make it a valuable component in the creation of new agrochemicals, potentially leading to advancements in pest control and crop protection.
Further research and studies are necessary to fully understand the scope of 4-CHLORO-7-IODOQUINAZOLINE's applications and to harness its potential in both the pharmaceutical and agrochemical industries.
Check Digit Verification of cas no
The CAS Registry Mumber 202197-78-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,2,1,9 and 7 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 202197-78:
(8*2)+(7*0)+(6*2)+(5*1)+(4*9)+(3*7)+(2*7)+(1*8)=112
112 % 10 = 2
So 202197-78-2 is a valid CAS Registry Number.
202197-78-2Relevant articles and documents
Novel quinazoline-containing compound, and intermediate and application thereof
-
, (2021/06/12)
The present invention discloses a quinazoline-containing compound having the formula (IA), (IB) or (IC), or a pharmaceutically acceptable salt or a prodrug molecule thereof. The compound is suitable for use as an Aurora kinase inhibitor and is thus suitable for the treatment of Aurora-mediated diseases characterized by excessive or abnormal cell proliferation, for example, cancer.
Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
-
, (2015/12/18)
A pharmaceutical formulation comprising the compound of formula
Anilinoquinazaolines as protein tyrosine kianse inhibitors
-
Page/Page column 47, (2008/06/13)
Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.